A
3.83
0.05 (1.32%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Arbutus Biopharma Corporation | Bullish | Mixed |
Stockmoo Score
1.8
|
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (Jefferies, 82.77%) | Buy |
| Median | 5.00 (30.55%) | |
| Low | 5.00 (HC Wainwright & Co., 30.55%) | Buy |
| 5.00 (JMP Securities, 30.55%) | Buy | |
| Average | 5.67 (48.04%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 3.81 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 05 Sep 2024 | 7.00 (82.77%) | Buy | 4.49 |
| JMP Securities | 02 Aug 2024 | 5.00 (30.55%) | Buy | 3.74 |
| HC Wainwright & Co. | 07 Jun 2024 | 5.00 (30.55%) | Buy | 3.20 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2024 | Announcement | Arbutus to Participate in Two Upcoming Investor Conferences |
| 01 Aug 2024 | Announcement | Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
| 18 Jul 2024 | Announcement | Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |